Evidence map›Paper›PMID 35673665›Full record

ArticleSurgical neurology international2022

Myeloid sarcoma of the skull base: A case report and systematic literature review.

Prazwal Athukuri, A Basit Khan, Ron Gadot, Monira Haque, Sungho Lee, K Kelly Gallagher, Martha P Mims, Gustavo A Rivero, Andreia Barbieri, Akash J Patel and 1 more

Open access · hybridAbstract readCase Reports
In one paragraph

Article in Surgical neurology international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Myeloid sarcoma of the skull base: a brief review of the literature and a rare case confused radiologically with end plaque meningioma.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Review
  2. Cerebral myeloid sarcoma (Chloroma): Report of a rare entity.International journal of surgery case reports · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Prazwal AthukuriDepartment of Neurosurgery, Baylor College of Medicine, Houston, Texas, United States.
A Basit KhanDepartment of Neurosurgery, Baylor College of Medicine, Houston, Texas, United States.
Ron GadotDepartment of Neurosurgery, Baylor College of Medicine, Houston, Texas, United States.
Monira HaqueDepartment of Neurosurgery, Baylor College of Medicine, Houston, Texas, United States.
Sungho LeeDepartment of Neurosurgery, Baylor College of Medicine, Houston, Texas, United States.
K Kelly GallagherDepartment of Neurosurgery, Baylor College of Medicine, Houston, Texas, United States.
Martha P MimsDepartment of Neurosurgery, Baylor College of Medicine, Houston, Texas, United States.
Gustavo A RiveroDepartment of Neurosurgery, Baylor College of Medicine, Houston, Texas, United States.
Andreia BarbieriDepartment of Neurosurgery, Baylor College of Medicine, Houston, Texas, United States.
Akash J PatelDepartment of Neurosurgery, Baylor College of Medicine, Houston, Texas, United States.
Ali JalaliDepartment of Neurosurgery, Baylor College of Medicine, Houston, Texas, United States.
Baylor College of Medicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Myeloid sarcoma (MS), or chloroma, is a rare extramedullary malignant tumor that consists of undifferentiated granulocytic cells, and it is most commonly associated with acute myeloid leukemia (AML). Intracranial MS accounts for 0.4% of MS cases, and involvement of the skull base and visual dysfunction is rarely reported. However, the optimal treatment and response to treatment of skull base MS in the presence of visual symptoms is unknown. Case Description: A 30-year-old male with a history of AML presented with rapidly progressive vision loss and a sellar and parasellar mass with bilateral cavernous sinus and optic nerve encasement. The patient underwent endoscopic endonasal transsphenoidal biopsy revealing intracranial MS. He was treated postoperatively with high-dose intravenous and intrathecal cytarabine and had complete restoration of his vision by postoperative day 11. A systematic review of the literature identified six cases of skull base MS, five of whom presenting with visual symptoms. All patients underwent systemic chemotherapy with cytarabine and/or cyclophosphamide, with infrequent use of intrathecal chemotherapy or radiation. Those with reported visual outcomes were diagnosed 4 months or longer after symptom onset and demonstrated no visual improvement with treatment. Conclusion: Skull base MS is a rare disease entity with a high prevalence of visual dysfunction. Our patient's complete disappearance of intracranial disease and resolution of visual symptoms with systemic and intrathecal chemotherapy highlight the importance of timely diagnosis and appropriate treatment without a need for direct surgical decompression.

Indexed as

Acute myeloid leukemiaChloromaMyeloid sarcomaParasellarSkull base

Identifiers

PMID35673665
PMCPMC9168333
OpenAlexW4281727526

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.